Vitamin D-ghrelin conjugates
AssigneeExtend Biosciences, Inc.
InventorsTarik Soliman, Laura M. Hales, Howard P. Sard, Mukkanti Amere
Life of this patent
Estimating the term…
Abstract
The invention provides carriers that enhance the absorption, half-life or bioavailability of Ghrelin peptides. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.
Claims25
A carrier-drug conjugate, comprising a targeting group that is vitamin D that is not hydroxylated at the Carbon 1 position stably linked to a therapeutic peptide having Ghrelin activity comprising an amino acid sequence with at least a 90% sequence identity to SEQ ID NO:5.
A pharmaceutical composition, comprising:
- (a) a therapeutic peptide having Ghrelin activity comprising an amino acid sequence with at least a 90% sequence identity to SEQ ID NO:5,
- (b) a stably attached scaffold,
- (c) a targeting group that is vitamin D that is not hydroxylated at the Carbon 1 position,
- wherein after administration to a first subject, said therapeutic peptide has a half life measured by an Enzyme Linked Immunosorbant Assay (ELISA) analysis of blood samples taken at a plurality of time points that is greater than a half life of said therapeutic peptide administered to a second subject without said attached scaffold and targeting group as measured by said ELISA analysis of blood samples taken at said plurality of time points.
A carrier-drug conjugate, comprising a stably linked targeting group that is vitamin D that binds a vitamin D binding protein with a higher affinity than said carrier-drug conjugate binds to a vitamin D receptor, wherein said carrier-drug conjugate comprises a therapeutic peptide having Ghrelin activity further comprising an amino acid sequence with at least a 90% sequence identity to SEQ ID NO:5.
A pharmaceutical composition, comprising:
- (a) a therapeutic peptide having Ghrelin activity comprising an amino acid sequence with at least a 90% sequence identity to SEQ ID NO:5,
- (b) a stably attached scaffold,
- (c) a targeting group that is Vitamin D,
- wherein after administration to a first subject, said therapeutic peptide has a half life measured by an ELISA analysis of blood samples taken at a plurality of time points that is greater than a half life of said therapeutic peptide administered to a second subject without said attached scaffold and targeting group as measured by said ELISA analysis of blood samples taken at said plurality of time points.
Dependencies are inferred from the claim text.